Relationship Between Serum Uric Acid-to-Creatinine Ratio and the Risk of Metabolic-Associated Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus

References

• Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1991. doi:10.1053/j.gastro.2019.11.312
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. doi:10.1002/hep.29367
   PubMed Web of Science ®Google Scholar
• Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016;65(8):1096–1108. doi:10.1016/j.metabol.2016.01.001
   PubMed Web of Science ®Google Scholar
• Arrese M, Barrera F, Triantafilo N, Arab JP. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Rev Gastroenterol Hepatol. 2019;13(9):849–866. doi:10.1080/17474124.2019.1649981
   PubMed Web of Science ®Google Scholar
• Hediger MA, Johnson RJ, Miyazaki H, Endou H. Molecular physiology of urate transport. Physiology. 2005;20:125–133. doi:10.1152/physiol.00039.2004
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183–1190. doi:10.1161/01.HYP.0000069700.62727.C5
   PubMed Web of Science ®Google Scholar
• Chen YL, Li H, Li S, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 2021;21(1):212. doi:10.1186/s12876-021-01782-w
   PubMed Web of Science ®Google Scholar
• Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: a meta-analysis. Acta Med Indones. 2017;49(2):136–147.
   PubMed Web of Science ®Google Scholar
• Al-Daghri NM, Al-Attas OS, Wani K, Sabico S, Alokail MS. Serum uric acid to creatinine ratio and risk of metabolic syndrome in Saudi type 2 diabetic patients. Sci Rep. 2017;7(1):12104. doi:10.1038/s41598-017-12085-0
   PubMed Web of Science ®Google Scholar
• Li M, Gu L, Yang J, Lou Q. Serum uric acid to creatinine ratio correlates with β-cell function in type 2 diabetes. Diabetes Metab Res Rev. 2018;34(5):e3001. doi:10.1002/dmrr.3001
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021
   PubMed Web of Science ®Google Scholar
• Adinolfi LE, Petta S, Fracanzani AL, et al. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: a prospective study. Diabetes Obes Metab. 2020;22(12):2408–2416. doi:10.1111/dom.14168
   PubMed Web of Science ®Google Scholar
• Adinolfi LE, Petta S, Fracanzani AL, et al. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: a prospective multicentre study. Atherosclerosis. 2020;296:40–47. doi:10.1016/j.atherosclerosis.2020.01.010
   PubMed Web of Science ®Google Scholar
• Sasso FC, Pafundi PC, Caturano A, et al. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. Nutr Metab Cardiovasc Dis. 2021;31(8):2345–2353. doi:10.1016/j.numecd.2021.04.016
   PubMed Web of Science ®Google Scholar
• Rinaldi L, Pafundi PC, Galiero R, et al. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review. Antioxidants. 2021;10(2):270.
   Web of Science ®Google Scholar
• Caturano A, Acierno C, Nevola R, et al. Non-alcoholic fatty liver disease: from pathogenesis to clinical impact. Processes. 2021;9(1):135. doi:10.3390/pr9010135
   Web of Science ®Google Scholar
• Masarone M, Rosato V, Aglitti A, et al. Liver biopsy in type 2 diabetes mellitus: steatohepatitis represents the sole feature of liver damage. PLoS One. 2017;12(6):e0178473. doi:10.1371/journal.pone.0178473
   PubMed Web of Science ®Google Scholar
• Wijarnpreecha K, Panjawatanan P, Lekuthai N, Thongprayoon C, Cheungpasitporn W, Ungprasert P. Hyperuricaemia and risk of nonalcoholic fatty liver disease: a meta-analysis. Liver Int. 2017;37(6):906–918. doi:10.1111/liv.13329
   PubMed Web of Science ®Google Scholar
• Zheng X, Gong L, Luo R, et al. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. Lipids Health Dis. 2017;16(1):202. doi:10.1186/s12944-017-0531-5
   Web of Science ®Google Scholar
• Liu J, Xu C, Ying L, et al. Relationship of serum uric acid level with non-alcoholic fatty liver disease and its inflammation progression in non-obese adults. Hepatol Res. 2017;47(3):E104–E112. doi:10.1111/hepr.12734
   PubMed Web of Science ®Google Scholar
• Wu SJ, Zhu GQ, Ye BZ, et al. Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults: a large population-based study. Medicine. 2015;94(17):e802. doi:10.1097/MD.0000000000000802
   PubMed Web of Science ®Google Scholar
• Kawamoto R, Tabara Y, Kohara K, Kusunoki T, Abe M, Miki T. Serum uric acid is more strongly associated with impaired fasting glucose in women than in men from a community-dwelling population. PLoS One. 2013;8(6):e65886. doi:10.1371/journal.pone.0065886
   PubMed Web of Science ®Google Scholar
• Zelber-Sagi S, Ben-Assuli O, Rabinowich L, et al. The association between the serum levels of uric acid and alanine aminotransferase in a population-based cohort. Liver Int. 2015;35(11):2408–2415. doi:10.1111/liv.12842
   Web of Science ®Google Scholar
• Hwang IC, Suh SY, Suh AR, Ahn HY. The relationship between normal serum uric acid and nonalcoholic fatty liver disease. J Korean Med Sci. 2011;26(3):386–391. doi:10.3346/jkms.2011.26.3.386
   PubMed Web of Science ®Google Scholar
• Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500–514. doi:10.1016/j.tem.2021.04.008
   PubMed Web of Science ®Google Scholar
• Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293(2):C584–596. doi:10.1152/ajpcell.00600.2006
   PubMed Web of Science ®Google Scholar
• Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25(2):210–216. doi:10.1097/BOR.0b013e32835d951e
   PubMed Web of Science ®Google Scholar
• Lanaspa MA, Sanchez-Lozada LG, Choi YJ, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem. 2012;287(48):40732–40744. doi:10.1074/jbc.M112.399899
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021;22(8):4156. doi:10.3390/ijms22084156
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–1846. doi:10.1002/hep.24001
   PubMed Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048. doi:10.1016/j.metabol.2015.12.012
   PubMed Web of Science ®Google Scholar
• Park SH, Kim BI, Yun JW, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol. 2004;19(6):694–698. doi:10.1111/j.1440-1746.2004.03362.x
   Web of Science ®Google Scholar
• Zhu Y, Hu Y, Huang T, et al. High uric acid directly inhibits insulin signalling and induces insulin resistance. Biochem Biophys Res Commun. 2014;447(4):707–714. doi:10.1016/j.bbrc.2014.04.080
   PubMed Web of Science ®Google Scholar
• Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60(4):1258–1269. doi:10.2337/db10-0916
   PubMed Web of Science ®Google Scholar
• Afzali A, Weiss NS, Boyko EJ, Ioannou GN. Association between serum uric acid level and chronic liver disease in the United States. Hepatology. 2010;52(2):578–589. doi:10.1002/hep.23717
   PubMed Web of Science ®Google Scholar
• Choi YJ, Shin HS, Choi HS, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest. 2014;94(10):1114–1125. doi:10.1038/labinvest.2014.98
   PubMed Web of Science ®Google Scholar
• Ackerman Z, Oron-Herman M, Grozovski M, et al. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension. 2005;45(5):1012–1018. doi:10.1161/01.HYP.0000164570.20420.67
   PubMed Web of Science ®Google Scholar
• Wan X, Xu C, Lin Y, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64(4):925–932. doi:10.1016/j.jhep.2015.11.022
   PubMed Web of Science ®Google Scholar
• Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS One. 2012;7(10):e47948. doi:10.1371/journal.pone.0047948
   PubMed Web of Science ®Google Scholar
• Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, Smirčić Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(48):18070–18091. doi:10.3748/wjg.v20.i48.18070
   PubMed Web of Science ®Google Scholar
• Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822–1832. doi:10.1038/s41591-019-0675-0
   PubMed Web of Science ®Google Scholar
• Xie D, Zhao H, Lu J, et al. High uric acid induces liver fat accumulation via ROS/JNK/AP-1 signaling. Am J Physiol Endocrinol Metab. 2021;320(6):E1032–e1043. doi:10.1152/ajpendo.00518.2020
   PubMed Web of Science ®Google Scholar
• Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67(5):1739–1742. doi:10.1111/j.1523-1755.2005.00273.x
   PubMed Web of Science ®Google Scholar
• Ucar F, Sezer S, Erdogan S, Akyol S, Armutcu F, Akyol O. The relationship between oxidative stress and nonalcoholic fatty liver disease: its effects on the development of nonalcoholic steatohepatitis. Redox Rep. 2013;18(4):127–133. doi:10.1179/1351000213Y.0000000050
   PubMed Web of Science ®Google Scholar
• Tariq Z, Green CJ, Hodson L. Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)? Liver Int. 2014;34(7):e180–e190. doi:10.1111/liv.12523
   Web of Science ®Google Scholar
• Wang M, Zhao D, Li GW, et al. [Correlation between serum uric acid and insulin resistance]. Zhonghua Yi xue Za Zhi. 2007;87(46):3260–3263. Chinese.
   Google Scholar
• Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep. 2011;13(2):160–166. doi:10.1007/s11926-011-0162-1
   PubMed Web of Science ®Google Scholar
• Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J. 2006;27(10):1174–1181. doi:10.1093/eurheartj/ehi879
   PubMed Web of Science ®Google Scholar